MYB and central nervous system cancer: Based on this unexpected therapeutic outcome, genome-wide DNA methylation array was employed and the sample was classified into the methylation class “Low-grade glioma, MYB(L1) altered.” Additionally, RT-PCR revealed the presence of MYB::QKI fusion.